VCEL logo

Vericel Corporation Stock Price

NasdaqGM:VCEL Community·US$2.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 15 Fair Values set on narratives written by author

VCEL Share Price Performance

US$46.34
9.52 (25.86%)
US$57.14
Fair Value
US$46.34
9.52 (25.86%)
18.9% undervalued intrinsic discount
US$57.14
Fair Value
Price US$46.34
AnalystConsensusTarget US$57.14
AnalystLowTarget US$55.00
AnalystHighTarget US$70.00

VCEL Community Narratives

·
Fair Value US$57.14 18.9% undervalued intrinsic discount

Expanding Regenerative Therapies Will Open New Market Horizons

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
·
Fair Value US$55 15.7% undervalued intrinsic discount

Expanded Cell Therapy Pipeline Will Face Execution Risks Yet Ultimately Support Healthier Business

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$70 33.8% undervalued intrinsic discount

Expanded Cell Therapy Capacity And Burn Care Franchise Will Drive Multiyear Upside Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$57.14
18.9% undervalued intrinsic discount
Revenue
17.17% p.a.
Profit Margin
17.38%
Future PE
44.85x
Price in 2029
US$69.18
US$70
33.8% undervalued intrinsic discount
Revenue
20.93% p.a.
Profit Margin
21.39%
Future PE
40.64x
Price in 2029
US$84.8

Trending Discussion

No trending discussion available.

Updated Narratives

VCEL logo

VCEL: Raised Guidance And Buyback Will Support Stronger Forward Repricing

Fair Value: US$55 15.7% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
VCEL logo

VCEL: Raised Outlook And New Headquarters Will Support Stronger Future Position

Fair Value: US$57.14 18.9% undervalued intrinsic discount
8 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
VCEL logo

VCEL: Strong Q1 Execution And BARDA Contract Will Drive Future Upside

Fair Value: US$70 33.8% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with solid track record.

1 Risk
3 Rewards

Vericel Corporation Key Details

US$306.3m

Revenue

US$77.9m

Cost of Revenue

US$228.4m

Gross Profit

US$204.2m

Other Expenses

US$24.2m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
0.47
74.56%
7.91%
0%
View Full Analysis

About VCEL

Founded
1989
Employees
398
CEO
Dominick Colangelo
WebsiteView website
www.vcel.com

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

Recent VCEL News & Updates

Narrative Update Jul 31

VCEL: Raised Guidance And Buyback Will Support Stronger Forward Repricing

Analysts have raised their fair value estimate for Vericel stock from $42.00 to $55.00, citing recent price target increases that follow reported MACI performance in Q2, as well as guidance they consider achievable for the second half of the year. Analyst Commentary Recent Street research on Vericel has focused on how current expectations for MACI and the broader MedTech backdrop feed into risk and reward for the stock.

Recent updates

No updates